For the quarter ended December 31, 2013, Rockwell reported a loss of ($8.3) million or ($0.21) per share, a 39% reduction compared to ($13.7) million or ($0.66) per share in the fourth quarter of 2012.

For the year ended December 31, 2013, Rockwell reported a loss of ($48.8) million or ($1.48) per share, a 9.7% reduction compared to ($54.0) million or ($2.65) per share in 2012.

"We had a very productive and successful 2013," stated, Robert L. Chioini, Founder, Chairman and CEO of Rockwell. "We completed our Triferic® Phase 3 pivotal study program and achieved outstanding clinical efficacy and safety results. We presented our compelling clinical data to the nephrology community via the most prominent conferences, including the PRIME study results showing Triferic reduces ESA a notable 35% overall and 74% among hypo-responders. We achieved all of our clinical milestones in 2013, and we are on track to submit our New Drug Application for Triferic® to the FDA shortly. Based upon exceptional clinical results, we believe Triferic® has high likelihood of gaining FDA approval and becoming the standard-of-care for iron maintenance therapy for dialysis
patients."

Mr. Chioini further stated, "Our sales continue to grow, led by our CitraPure® concentrate product line. We anticipate FDA manufacturing approval for Calcitriol will occur shortly and upon commercial launch we expect robust sales. Notably, R&D expense decreased significantly in the fourth quarter and we expect a similar decline quarterly through year-end 2014."

Conference Call Information

Rockwell Medical will be hosting a conference call to review its fourth quarter and 2013 year end results on Wednesday, February 26, 2014 at 4:30 pm ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438, or for international callers (678) 894-3975, passcode #84449204 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/

About Triferic™

Triferic™ is a unique iron compound that is delivered to the hemodialysis patient via dialysate, replacing the 5-7 mg of iron that is lost during every dialysis treatment. Triferic™ is introduced into the sodium bicarbonate concentrate on-site at the dialysis clinic, which is subsequently mixed into dialysate. Once in the dialysate, Triferic™ crosses the dialyzer membrane and enters the blood where it immediately binds to apo-transferrin and is taken to the bone marrow, similar to how dietary iron is processed in the human body. In completed clinical trials to date, Triferic™ has demonstrated that it can safely and effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell's lead drug candidate Triferic™ is in late-stage clinical development for the treatment of iron replacement in dialysis patients. Triferic™ delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials to date, Triferic™ has demonstrated that it can safely and effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose. Triferic® has completed the efficacy trials of its Phase 3 clinical study program (CRUISE-1 and CRUISE-2). Triferic® is expected to address an estimated $600M U.S. market.

Rockwell is preparing to launch its FDA approved generic drug Calcitriol, to treat secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol once it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and Triferic® upon FDA market approval.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic™ for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of the Triferic™ unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and Triferic® following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current
estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical'sSEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

ROCKWELL MEDICAL, INC. AND SUBSIDIARY

CONSOLIDATED INCOME STATEMENTS

For the three and twelve months ended December 31, 2013 and December 31, 2012

Three Months

Three Months

Twelve Months

Twelve Months

Ended

Ended

Ended

Ended

December 31,

December 31,

December 31,

December 31,

2013

2012

2013

2012

Sales

$13,964,624

$12,999,846

$52,379,543

$49,842,392

Cost of Sales

11,904,730

11,297,621

45,720,323

43,148,965

Gross Profit

2,059,894

1,702,225

6,659,220

6,693,427

Selling, General and Administrative

3,795,325

3,635,386

14,336,449

12,683,860

Research and Product Development

5,793,579

11,751,256

39,382,037

48,271,649

Operating Income (Loss)

(7,529,010)

(13,684,417)

(47,059,266)

(54,262,082)

Interest and Investment Income, net

69,317

11,034

98,101

241,518

Interest Expense

872,412

105

1,822,147

951

Income (Loss) Before Income Taxes

(8,332,105)

(13,673,488)

(48,783,312)

(54,021,515)

Income Tax Expense

--

--

--

--

Net Income (Loss)

$(8,332,105)

$(13,673,488)

$(48,783,312)

$(54,021,515)

Basic Earnings (Loss) per Share

($.21)

($.66)

($1.48)

($2.65)

Diluted Earnings (Loss) per Share

($.21)

($.66)

($1.48)

($2.65)

ROCKWELL MEDICAL, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

As of December 31, 2013 and 2012

December 31,

December 31,

ASSETS

2013

2012

Cash and Cash Equivalents

$11,881,451

$4,711,730

Investments Available for Sale

12,034,622

--

Accounts Receivable, net of a reserve of $37,000 in 2013 and $26,000 in 2012

4,578,319

4,431,932

Inventory

2,799,648

2,649,639

Other Current Assets

623,734

1,356,131

Total Current Assets

31,917,774

13,149,432

Property and Equipment, net

1,648,949

1,858,442

Intangible Assets

499,715

666,744

Goodwill

920,745

920,745

Other Non-current Assets

1,374,941

429,723

Total Assets

$36,362,124

$17,025,086

LIABILITIES AND SHAREHOLDERS' EQUITY

Note Payable Capitalized Lease Obligations

$2,308,145

$ --

Capitalized Lease Obligations Capitalized Lease Obligations

--

2,280

Accounts Payable

8,686,153

14,833,565

Accrued Liabilities

6,647,828

12,015,978

Customer Deposits

207,545

135,133

Total Current Liabilities

17,849,671

26,986,956

Long Term Debt

17,916,914

--

Shareholders' Equity:

Common Shares, no par value, 40,110,661 and 21,494,696 shares issued and outstanding